Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab as Adjuvant Therapy in Resected Pancreatic Cancer
NCT03038477Phase 2Withdrawn
- Sponsor
- University of Colorado Denver
- Start
- Jun 2017
- Primary completion
- Apr 2019
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab in pancreatic ductal adenocarcinoma (PDAC), sponsored by University of Colorado Denver. Planned start Jun 2017; status: withdrawn.
02
Drugs
durvalumab
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03038477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03038477.